Abstract
Prenatal exposure to environmental contaminants is a significant health concern because it has the potential to interfere with host metabolism, leading to adverse health effects in early childhood and later in life. Growing evidence suggests that genetic and environmental factors, as well as their interactions, play a significant role in the development of autoimmune diseases. In this study, we hypothesized that prenatal exposure to environmental contaminants impacts cord serum metabolome and contributes to the development of autoimmune diseases. We selected cord serum samples from All Babies in Southeast Sweden (ABIS) general population cohort, from infants who later developed one or more autoimmune-mediated and inflammatory diseases: celiac disease (CD), Crohn’s disease (IBD), hypothyroidism (HT), juvenile idiopathic arthritis (JIA), and type 1 diabetes (T1D) (all cases, N = 62), along with matched controls (N = 268). Using integrated exposomics and metabolomics mass spectrometry (MS) based platforms, we determined the levels of contaminants and metabolites. Differences in exposure levels were found between the controls and those who later developed various diseases. High contaminant exposure levels were associated with changes in metabolome, including amino acids and free fatty acids. Specifically, we identified marked associations between metabolite levels and exposure levels of deoxynivalenol (DON), bisphenol S (BPS), and specific per- and polyfluorinated substances (PFAS). Our study suggests that prenatal exposure to specific environmental contaminants alters the cord serum metabolomes, which, in turn, might increase the risk of various immune-mediated disease later in life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swedish Research Council [grant number 2020-03674; to TH], Formas [grant number 2019-00869; to TH], and by the 'Inflammation in human early life: targeting impacts on life-course health' (INITIALISE) consortium funded by the Horizon Europe Program of the European Union under Grant Agreement 101094099 (to T.H., E.W.T., M.O., and J.L.). The ABIS cohort study (JL) was supported by Barndiabetesfonden (Swedish Child Diabetes Foundation), the Swedish Council for Working Life and Social Research [grant numbers FAS2004-1775 and FAS2004-1775], Swedish Research Council [Grant/Award Numbers: K2005-72×-11242-11A and K2008-69×-20826-01-4, K2008-69×-20826-01-4], Ostgota Brandstodsbolag, Medical Research Council of Southeast Sweden (FORSS), JDRF Wallenberg Foundation [Grant/Award Number: K 98-99D-12813-01A], Joanna Cocozza Foundation and ALF and LfoU grants from Region Ostergotland and Linkoping University, Sweden.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed in accordance with the Declaration of Helsinki. The ABIS study was approved by the Research Ethics Committees of the Faculty of Health Sciences at Linkoping University, Sweden, 1997/96287 and 2003/03-092 and the Medical Faculty of Lund University, Sweden (DNR 99227, DNR 99321). All participating parents gave their informed consent to participate in ABIS after oral, written and video information. ABIS connection to national register approved by the Research Ethics Committees of the Faculty of Health Sciences at Linkoping University, Sweden, DNR 05-513, and 2018/380-32.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data accessibility
Data are available upon reasonable request after ethical approvement and an appropriate institutional collaboration agreement. These data are not available to access in a repository owing to concern that the identity of patients might be revealed inadvertently.
